ReviewJournal of clinical and translational hepatology2014
Thrombosis Associated with Viral Hepatitis.
Review in Journal of clinical and translational hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review.Internal and emergency medicine · 2018Pooled it
- The Platelet-Virus Axis in Human Disease.Viruses · 2026Review
- Thrombotic risk in hepatitis C: Interplay between hepatic dysfunction, viral-driven inflammation, and cardiovascular consequences.World journal of virology · 2025Review
- Plasminogen as a Marker for Assessing Thrombotic Risk During Hepatitis in Cameroon: Case-Control Study.Health science reports · 2025Article
- From the right ventricle to the descending aorta: a Case Report of complex thrombotic events in a patient with nephrotic syndrome.Frontiers in pharmacology · 2025Article
- Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021.Therapeutic advances in hematology · 2025Article
- Correlation Between Thrombin Generation and Hepatic Fibrosis in Chronic Liver Diseases.Cureus · 2024Article
- Hepatitis B virus and cytomegalovirus coinfection in an older patient: a case report.The Journal of international medical research · 2024Article
- Interaction between coagulation and inflammatory system in liver disease: re-focus on hematological markers.Biomarkers in medicine · 2024Article
- A Young Male With Non-cirrhotic Cryptogenic Portal Cavernoma: An Authoritative Case Study.Cureus · 2023Article
- Article
- Venous thromboembolism in viral diseases: A comprehensive literature review.Health science reports · 2023Article
- Map of thrombogenesis in viral infections and viral-driven tumours.Discover oncology · 2023Review
- A Machine Learning Framework for Assessing the Risk of Venous Thromboembolism in Patients Undergoing Hip or Knee Replacement.Journal of healthcare informatics research · 2022Article
- Cerebral Venous Thrombosis as The Sole Presenting Manifestation of Human Immunodeficiency Virus and Hepatitis B Virus Co-Infection.Medical research archives · 2022Article
- Article
- Acute limb ischemia among patients with COVID-19 infection.Journal of vascular surgery · 2022Review
- Idiopathic Portal Vein Thrombosis in a Non-cirrhotic Patient: A Discussion of Management and a Review of Literature.Cureus · 2021Article
- The contact system in liver injury.Seminars in immunopathology · 2021Review
- Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis may promote the development of venous thromboembolism (VTE) and, more specifically, portal vein thrombosis (PVT). In this narrative review, we summarize the clinical data and discuss the possible pathogenetic roles of cytomegalovirus (CMV), Epstein-Barr virus (EBV), and hepatitis A, B, and C viruses (HAV, HBV, HCV) in the occurrence of VTE. CMV is the first qualified candidate to enter the list of VTE minor risk factors, and in the rare case of fulminant infection, both EBV and CMV, like any severe infection or inflammatory disease, increase risk for thrombosis. In chronic hepatitis B and C, it remains controversial whether antiphospholipid antibodies are important for thrombotic complications or merely an epiphenomenon. Retinal vein occlusion described in chronic hepatitis C is usually attributed to the treatment with interferon. Eltrombopag, used for HCV-related thrombocytopenia, has been associated with increased thrombotic risk. The imbalance between procoagulant and anticoagulant factors associated with chronic liver disease may have clinical implications. This may help to explain why these patients are not protected from clinical events such as VTE, PVT, and the progression of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.